Minerva Neurosciences (NERV) Given News Sentiment Rating of 0.19

News stories about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.0411019506218 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

• Minerva Neurosciences, Inc (NASDAQ:NERV) Posts Earnings Results, Beats Estimates By $0.07 EPS (americanbankingnews.com)
• BRIEF-Minerva Neurosciences ‍says phase 2B trial with MIN-117 planned for late 2017 (reuters.com)
• Minerva Neurosciences Inc : Investor Network: Minerva Neurosciences Inc to Host Earnings Call (4-traders.com)
• Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates (finance.yahoo.com)
• Minerva Neurosciences reports 2Q loss (finance.yahoo.com)

Minerva Neurosciences (NERV) traded up 3.12% during trading on Friday, hitting $6.60. The company had a trading volume of 130,007 shares. The company’s 50 day moving average price is $8.65 and its 200-day moving average price is $8.59. Minerva Neurosciences has a 12 month low of $6.30 and a 12 month high of $14.92. The company’s market cap is $242.25 million.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.07. During the same quarter last year, the business posted ($0.18) EPS. Equities analysts expect that Minerva Neurosciences will post ($1.35) earnings per share for the current year.

Several equities analysts have issued reports on NERV shares. ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Monday, May 29th. Zacks Investment Research raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. BidaskClub lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $20.00 price objective (up previously from $17.00) on shares of Minerva Neurosciences in a report on Thursday, June 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $16.67.

ILLEGAL ACTIVITY NOTICE: This report was first reported by [[site]] and is the property of of [[site]]. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at [[permalink]].

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.